Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3B open-label study of vonicog alfa and octocog alfa (Advate) in severe von Willebrand disease
2018-003453-16Phase 3Completed
- Sponsor
- Baxalta
- Start
- Jan 2019
- Countries
- 1
01
Overview
Phase 3, open-label trial of von Willebrand factor concentrate in von Willebrand disease (VWD) (3 arms), sponsored by Baxalta. Started Jan 2019; status: completed.
02
Drugs
von Willebrand factor concentrate
03
Conditions
von Willebrand disease (VWD)
Beyond the preview
Go deeper on 2018-003453-16.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-003453-16.